Status:

TERMINATED

Metabolic Effects of Natriuretic Peptide Hormones

Lead Sponsor:

VA Office of Research and Development

Conditions:

Obesity

Cardiovascular Physiological Phenomena

Eligibility:

All Genders

18-40 years

Phase:

PHASE4

Brief Summary

Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on met...

Detailed Description

Objective: The natriuretic peptide (NP) hormonal system is well-known for its important role in blood pressure regulation. However, accumulating evidence suggests that the NPs have significant effects...

Eligibility Criteria

Inclusion

  • Men and women ages 18-40 years
  • Body Mass Index (BMI): 18.5 BMI\<25 kg/m2 (lean) or BMI \> or = 30 kg/m2 (obese)

Exclusion

  • Significant cardiovascular disease (including heart failure and atrial fibrillation)
  • Significant pulmonary, liver, or renal disease
  • Diabetes Mellitus
  • Significant Hypertension
  • Hypotension
  • Thyroid dysfunction
  • Active malignancy
  • Current or recent use of glucocorticoids
  • Current use of antihypertensive medications, including diuretics
  • Current use of medications affecting glucose metabolism, including metformin
  • Current use of amphetamines or other medications known to affect energy homeostasis
  • Currently pregnant or breastfeeding, or unwilling to avoid becoming pregnant or breastfeeding during study duration
  • Significant claustrophobia that would prevent the use of the metabolic cart as part of the study protocol
  • Currently abnormal serum or plasma sodium or potassium level
  • Known hypersensitivity to recombinant human b-type natriuretic peptide, BNP(1-32) (nesiritide), or phenylephrine
  • Hemoglobin A1c (HbA1c) \>= 6.5%
  • Liver Function Tests (LFTs) elevated \>2x upper limit of normal
  • Estimated Glomerular Filtration Rate (eGFR) \<60 ml/min
  • Currently abnormal thyroid stimulating hormone (TSH)

Key Trial Info

Start Date :

July 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2019

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03397966

Start Date

July 1 2018

End Date

May 1 2019

Last Update

November 25 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Tennessee Valley Healthcare System Nashville Campus, Nashville, TN

Nashville, Tennessee, United States, 37212-2637

2

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Metabolic Effects of Natriuretic Peptide Hormones | DecenTrialz